SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a strong earnings report, driven by AI demand and government support, fueling investor confidence. The community is discussing the potential for a short squeeze and future growth, particularly with new partnerships and foundry progress. Amidst the positive sentiment, some remain cautious, pointing to forward PE ratios and potential market corrections.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending amid discussions around potential layoffs and cost-cutting measures as the company prepares for the R2 SUV launch in 2026. The community is actively debating the impact of these measures on Rivian's future and its ability to compete in the EV market, with some users expressing concerns about cash burn and slumping sales, while others see a potential opportunity to accumulate shares before a future upswing.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont (NEM) is trending as investors digest recent earnings and assess its future direction amid fluctuating gold prices. Community discussions revolve around the company's financial health, its strategy for optimizing assets, and the potential impact of a new CEO. Some traders express concerns about short-term volatility, while others see long-term value in the gold mining sector.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

$BALLIN is gaining attention, particularly among users of Phantom Wallet, with community members highlighting positive momentum. The coin is discussed with terms like "moonshot" and "breakout," indicating anticipation of significant price movement. Conversations suggest a focus on community and shared success.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

DECK is trending due to mixed reactions to earnings, with some investors seeing a buying opportunity after the dip, while others express concerns about forward guidance and potential impacts from tariffs. Community discussions revolve around the company's valuation, growth prospects for Hoka and UGG brands, and the potential for share buybacks to influence the stock price. Overall, the stock's movement and future potential are heavily debated among investors.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber shares are trending amidst discussions around autonomous vehicle technology, fueled by its partnerships and the broader implications for the ride-sharing landscape. Community members are actively debating the potential impact of Waymo and Tesla's advancements on Uber's market position. Bullish sentiment remains due to Uber's established platform and expansion into delivery services, while some traders are closely monitoring technical indicators and potential pullback opportunities.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Recent chatter suggests a potential buyout of WBD is brewing, with community members actively discussing possible offers and the strategic implications for the media landscape. Some anticipate a bidding war, while others speculate about the timing and potential hurdles to a deal. Community members are debating what a fair price is, taking into account debt, studio assets, and competitive positioning.

Integer Holdings Corp. engages in the manufacture and development of medical devices and components. The firm has the following product lines: Cardio and Vascular, Cardiac Rhythm Management and Neuromodulation, and Other Markets. The company was founded by Wilson Greatbatch in 1970 and is headquartered in Plano, TX.

Integer Holdings Corp

Integer Holdings ($ITGR) is trending due to a significant stock drop, reportedly triggered by lowered sales guidance for 2025 and concerns about 2026 despite a Q3 earnings beat. The community is debating whether the sell-off was an overreaction, with some viewing it as a buying opportunity, while others cite CEO share sales and forecast revisions as reasons for caution.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Alaska Air Group is facing downward pressure due to a technology outage that grounded flights and a reduced 2025 profit outlook, prompting concerns among investors. The community is actively discussing the impact of these operational challenges and revised guidance. Some believe it may recover while others are looking at entry points in the $30 range.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as investors discuss its recent deployment of the veriScan biometric identity platform at Chicago O'Hare International Airport. Community members are speculating on potential TSA contracts and further airport expansions, driving optimism around the AI analytics company's role in enhancing security and streamlining passenger processing. Bullish sentiment is fueled by the company's AI capabilities and potential growth within the national security sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The Phase 2 trial showed VTX3232 cut key inflammation markers like hsCRP by about 78% and IL-6 to below risk thresholds, reinforcing its anti-inflammatory potential.</li><li>Combination treatment with semaglutide led to further reductions in liver inflammation and cardiovascular biomarkers, with no major safety issues reported.</li><li>On Stocktwits, retail traders debated whether VTX3232 holds greater promise as a combo therapy than a standalone drug.</li></ul>Retail chatter around Ventyx Biosciences surged&nbsp;late Wednesday after the biotechnology company announced positive topline results from a Phase 2 study of its oral anti-inflammatory drug, VTX3232, in participants with obesity and cardiovascular risk factors.<h2 class="st-heading-2">Strong Reductions In Inflammatory Markers</h2>The study followed 175 participants in the trial, which tested VTX3232 as both a standalone therapy and alongside semaglutide. These were compared to placebo groups.In a statement, Ventyx said those taking the drug demonstrated strong evidence of an anti-inflammatory effect of the drug as evidenced by reductions in two biomarkers of cardiovascular risk, high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).In the monotherapy group, hsCRP levels decreased by approximately 78% by week 12, in contrast to an increase observed in the placebo group. Levels of IL-6 also dropped to below 1.65 nanograms per liter, which is a marker for lower heart risk.The firm also said the drug reduced levels of lipoprotein(a), fibrinogen, and liver inflammation, showing signs of an anti-inflammatory effect across multiple measures.<h2 class="st-heading-2">Expert View</h2>CEO Raju Mohan said the observed effects on hsCRP, IL-6, and Lp(a) suggest VTX3232 could represent a new class of oral anti-inflammatory therapies.Peter Libby, MD of Mass General Brigham, said elevated CRP levels are a strong predictor of cardiovascular risk and that new NLRP3 inhibitors may complement cholesterol-lowering treatments.Chief Medical Officer Mark Forman said VTX3232 “robustly inhibited the NLRP3 pathway,” adding that combination treatment with semaglutide achieved further reductions in inflammation-related biomarkers.<h2 class="st-heading-2">Stocktwits Traders See Combo Potential</h2>On Stocktwits, retail sentiment for Ventyx was ‘extremely bullish’ amid an 18,600% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:974/139;" src="https://news.stocktwits-cdn.com/vtyx_ss_jpg_c8842a5cf1.webp" alt="vtyx ss.jpg" width="974" height="139"><figcaption>VTYX sentiment and message volume as of October 23 | Source: Stocktwits</figcaption></figure>One user&nbsp;expressed “mixed feelings” about the results, noting that while the data showed little effect on weight, liver disease (MASH), or lipids, VTX3232 appeared to be a strong candidate for use in combination therapies rather than as a standalone drug. They added that longer studies would be needed to define its target patient group and assess its value as a monotherapy.<stembedurl>https://stocktwits.com/aletz/message/633359533</stembedurl>Another user highlighted the company’s strong financial position, pointing out that Ventyx holds nearly $3 per share in cash and carries minimal debt.<stembedurl>https://stocktwits.com/Samb321/message/633346861</stembedurl><a href="https://stocktwits.com/symbol/VTYX">Ventyx’s stock</a> has risen 76% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ventyx’s stock (VTYX) has risen 76% so far in 2025. (Photo credit: Getty Images)

Ventyx Biosciences Stock: Retail Buzz Spikes After Phase 2 Win In Obesity And Heart Risk Study

The Phase 2 trial showed VTX3232 cut key inflammation markers like hsCRP by about 78% and IL-6 to below risk thresholds, reinforcing its anti-inflammatory potential.

Equity

Ventyx Biosciences, Inc. (VTYX) Is Up 20.81% in One Week: What You Should Know 

Does Ventyx Biosciences, Inc. (VTYX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Ventyx Biosciences (VTYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

VTYX Stock Rises on Strategic Equity Investment Deal With SNY

Shares of Ventyx Biosciences (NASDAQ: VTYX) gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi.
read more...

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

Ventyx Biosciences stock down over 24% on Monday after Phase 2 trial results for Crohn's disease drug VTX958 did not meet primary endpoint.
read more...

VTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX

VTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX VTYX...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)

The Law Offices of Frank R. Cruz reminds investors of the upcoming April 30, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Ventyx...

VTYX DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX

VTYX DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX VTYX...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX SHAREHOLDER ALERT...

The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX

The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX The Gross Law Firm Reminds Ventyx...

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Current Price	$6.55
Prev Close	$3.86
Open	$7.50
Dividend Yield	0.00%
50-Day Moving Average	$3.05
Beta	1.40
Avg. Volume	786,153.19
PE Ratio	-3.93

52-Week High	$7.82
52-Week Low	$0.783
Market Capitalization	$470.64M
EPS (Annual)	-$1.97
Price to Book	2.25
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

VTYX
Ventyx Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VTYX News

VTYXVentyx Biosciences Inc